Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07072793 · ClinicalTrials.gov registry record
A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 131,005
- Enrollment target
NCT07072793: Completed study, sponsored by Pfizer.
NCT07072793 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 131,005 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07072793 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 131,005 participants
- Enrollment target
Study Summary
The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work. The study compares two groups of participants who are confirmed to have mild-to moderated COVID-19 and who have high chances of the disease becoming severe. The two groups are: People who took the antiviral medication nirmatrelvir-ritonavir (also called Paxlovid) People who were eligible to receive antiviral medication but did not receive any. The participants will be selected from various health databases in the US between June 2021 and December 2022. The main goals are: To look at the characteristics of both groups of participants with COVID-19. To measure how much work these participants missed, including days off and sick leave, and the costs associated with this work loss. To compare work loss and costs between the two groups of participants, considering differences in their clinical and demographic characteristics. The study will evaluate at least 30 days of data from participants after they are confirmed to have COVID-19
Primary Outcome
Age group was categorized into following categories: 18-29 years, 30-39 years, 40-49 years, 50-64 years and 65-74 years. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represent
Interventions
- DRUG nirmatrelvir-ritonavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131,005 participants |
| Start Date | 2024-10-31 |
| Est. Completion | 2024-11-15 |
What the finished NCT07072793 record still lists
NCT07072793 is an observational study that tracks outcomes without assigning an intervention. Its 131,005 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which nirmatrelvir-ritonavir is the first listed.
NCT07072793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07072793 about?
NCT07072793 is a clinical study titled "A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe". The purpose of this study is to understand how COVID-19 affects people's ability to work and to calculate the costs associated with loss of work. The study compares two groups of participants who are confirmed to have mild-to moderated COVID-19 and who have high chances of the disease becoming seve...
What is the current status of trial NCT07072793?
This trial is currently completed. The enrollment target is 131,005 participants. The study started on 2024-10-31. Estimated completion is 2024-11-15.
What interventions are being tested in trial NCT07072793?
The interventions under investigation include: nirmatrelvir-ritonavir (DRUG).
Who is sponsoring clinical trial NCT07072793?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05994482 · 130,000 participants
Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
- NCT02693509 · 128,026 participants
Get With The Guidelines-Heart Failure Registry
- NCT03897374 · 120,000 participants
Strategic Targeting for Optimal Prevention of Cancer
- NCT06608758 · 120,000 participants
End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI